DK3442537T3 - (+)-azasetron til anvendelse i behandlingen af ørelidelser - Google Patents

(+)-azasetron til anvendelse i behandlingen af ørelidelser Download PDF

Info

Publication number
DK3442537T3
DK3442537T3 DK17717441.4T DK17717441T DK3442537T3 DK 3442537 T3 DK3442537 T3 DK 3442537T3 DK 17717441 T DK17717441 T DK 17717441T DK 3442537 T3 DK3442537 T3 DK 3442537T3
Authority
DK
Denmark
Prior art keywords
azasetron
treatment
ear disorders
ear
disorders
Prior art date
Application number
DK17717441.4T
Other languages
English (en)
Inventor
Jonas Dyhrfjeld-Johnsen
Original Assignee
Sensorion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sensorion filed Critical Sensorion
Priority claimed from PCT/EP2017/059058 external-priority patent/WO2017178645A1/en
Application granted granted Critical
Publication of DK3442537T3 publication Critical patent/DK3442537T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/5381,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DK17717441.4T 2016-04-14 2017-04-14 (+)-azasetron til anvendelse i behandlingen af ørelidelser DK3442537T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662322690P 2016-04-14 2016-04-14
EP16180192 2016-07-19
PCT/EP2017/059058 WO2017178645A1 (en) 2016-04-14 2017-04-14 (+)-azasetron for use in the treatment of ear disorders

Publications (1)

Publication Number Publication Date
DK3442537T3 true DK3442537T3 (da) 2024-03-25

Family

ID=65588799

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17717441.4T DK3442537T3 (da) 2016-04-14 2017-04-14 (+)-azasetron til anvendelse i behandlingen af ørelidelser

Country Status (15)

Country Link
US (2) US11612605B2 (da)
EP (1) EP4335508A2 (da)
JP (1) JP7158723B2 (da)
CN (1) CN109310698B (da)
AU (1) AU2023202897A1 (da)
CL (1) CL2018002930A1 (da)
DK (1) DK3442537T3 (da)
FI (1) FI3442537T3 (da)
HR (1) HRP20240453T1 (da)
IL (1) IL262305B (da)
MX (1) MX2018012587A (da)
NZ (1) NZ747201A (da)
RS (1) RS65379B1 (da)
SI (1) SI3442537T1 (da)
ZA (1) ZA201806894B (da)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016184900A1 (en) * 2015-05-18 2016-11-24 Sensorion Calcineurin inhibitors of the setron family for the treatment of hearing loss

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4695578A (en) 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
US5360800A (en) 1987-09-03 1994-11-01 Glaxo Group Limited Tetrahydro-1H-pyrido[4,3-b]indol-1-one derivatives
CA1304082C (en) 1987-10-22 1992-06-23 Tetsuya Tahara Benzoxazine compounds and pharmaceutical use thereof
GB9423511D0 (en) 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
GB0009914D0 (en) 2000-04-20 2000-06-07 Metris Therapeutics Limited Device
GB0104554D0 (en) * 2001-02-23 2001-04-11 Glaxo Group Ltd New uses
US20030044356A1 (en) 2001-04-20 2003-03-06 Jin Auh Composition for nasal solution sprays having effective component of 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one)
US20030229333A1 (en) * 2002-02-22 2003-12-11 Control Delivery Systems, Inc. Methods for treating otic disorders
GB0213869D0 (en) 2002-06-17 2002-07-31 Arakis Ltd The treatment of pain
EP1567163B1 (en) 2003-01-13 2007-04-11 Dynogen Pharmaceuticals Inc. Method of treating nausea, vomiting, retching or any combination thereof
TWI355936B (en) 2003-02-18 2012-01-11 Helsinn Healthcare Sa Uses of palonosetron hydrochloride
US20040204466A1 (en) 2003-04-14 2004-10-14 Orchid Chemicals And Pharmaceuticals Ltd. Treatment of bronchial asthma using 5-HT3 receptor antagonists
US20070265329A1 (en) 2006-05-12 2007-11-15 Devang Shah T Methods for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV)
EP2725035A1 (en) 2007-10-02 2014-04-30 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract
BRPI0915770A2 (pt) 2008-07-14 2015-11-03 Otonomy Inc composição de modulação de apoptose de liberação controlada e métodos para o tratamento de distúrbios ótológicos
PL2432467T3 (pl) 2009-05-20 2018-07-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Zastosowanie antagonistów receptora 5-ht3 serotoniny w leczeniu zaburzeń przedsionkowych ze zmianami chorobowymi
ES2432618T3 (es) * 2009-05-20 2013-12-04 Inserm (Institut National De La Santé Et De La Recherche Medicale) Antagonistas del receptor 5-HT3 de serotonina para usar en el tratamiento o prevención de una patología del oído interno con déficit vestibular
CN101786963B (zh) 2010-03-03 2013-05-08 山东众诚药业股份有限公司 阿扎司琼中间体的合成方法
EP2817009A1 (en) 2012-02-23 2014-12-31 INSERM - Institut National de la Santé et de la Recherche Médicale Calcineurin inhibitors for use in the treatment of lesional vestibular disorders
ES2785303T3 (es) 2012-07-16 2020-10-06 Univ Cornell Nicotinamida ribósido para tratar la pérdida auditiva
US9603935B2 (en) * 2013-07-31 2017-03-28 Bluepharma Oral dispersible films
CN104557906A (zh) 2015-01-21 2015-04-29 扬子江药业集团四川海蓉药业有限公司 一种盐酸阿扎司琼的制备方法
WO2016184900A1 (en) * 2015-05-18 2016-11-24 Sensorion Calcineurin inhibitors of the setron family for the treatment of hearing loss

Also Published As

Publication number Publication date
JP7158723B2 (ja) 2022-10-24
US11612605B2 (en) 2023-03-28
JP2019513780A (ja) 2019-05-30
RS65379B1 (sr) 2024-04-30
NZ747201A (en) 2023-02-24
AU2023202897A1 (en) 2023-05-25
IL262305A (en) 2018-11-29
US20230226071A1 (en) 2023-07-20
MX2018012587A (es) 2019-03-07
SI3442537T1 (sl) 2024-05-31
CN109310698B (zh) 2021-12-24
HRP20240453T1 (hr) 2024-06-21
US20190083503A1 (en) 2019-03-21
IL262305B (en) 2022-03-01
CL2018002930A1 (es) 2019-02-15
FI3442537T3 (fi) 2024-04-04
CN109310698A (zh) 2019-02-05
EP4335508A2 (en) 2024-03-13
ZA201806894B (en) 2023-03-29

Similar Documents

Publication Publication Date Title
DK3570844T3 (da) Azolopyrimidin til behandlingen af kræftrelaterede lidelser
DK3185876T3 (da) Sammensætninger og fremgangsmåder til behandling af neurologiske lidelser
DK3119397T3 (da) Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser
DK3334422T3 (da) Anvendelse af cannabidiolsyre i behandling af epilepsi
DK3261640T3 (da) 5ht-agonister til behandling af epilepsilidelser
DK3882250T3 (da) Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3481846T3 (da) 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande
DK3811943T3 (da) Forbindelse til anvendelse til behandling af øjenlidelser
DK3307262T3 (da) Forbindelser til anvendelse ved behandling af neuromuskulære lidelser
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
DK3288577T3 (da) Adiponectin-peptidomimetika til behandling af øjenlidelser
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK3102213T3 (da) Farmaceutiske sammensætninger til behandlingen af inflammatoriske lidelser
DK3390390T3 (da) Bipyrazolylderivater egnede til behandling af autoimmunsygdomme
DK3307296T3 (da) Timp2 til anvendelse til behandling af aldringsassocierede tilstande
DK3081263T3 (da) Sammensætninger og redskaber til behandling af glaukom
DK3242947T3 (da) Genterapi og elektroporese til behandling af maligniteter
DK3439661T3 (da) Fremgangsmåder til behandling af øjenlidelser
DK3374497T3 (da) Modificerede makrofager til anvendelse i behandlingen af kræft
DK3157522T3 (da) Muskarin-antagonister og kombinationer deraf til behandlingen af luftvejssygdomme i heste
DK3149049T3 (da) Il-22 til anvendelse til behandling af stofskiftesygdomme
DK3164123T3 (da) Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier
DK3522873T3 (da) Sammensætninger og fremgangsmåder til behandlingen af xerostomi
DK3122743T3 (da) Sammensætninger og fremgangsmåder til behandling af neurodegenerative sygdomme